Drug Combination Details
| General Information of the Combination (ID: C37122) | |||||
|---|---|---|---|---|---|
| Name | Sulforaphane NP Info | + | Everolimus Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Bladder cancer
[ICD-11: 2C94]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CDK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | IFI27 | Molecule Info | |||
| Up-regulation | Expression | REG1A | Molecule Info | |||
| In-vitro Model | RT-112 | CVCL_1670 | Bladder carcinoma | Homo sapiens | ||
| UM-UC-3 | CVCL_1783 | Bladder carcinoma | Homo sapiens | |||
| TCCSUP | CVCL_1738 | Bladder carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Chronic sulforaphane administration inhibits resistance to the mTOR-inhibitor everolimus in bladder cancer cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells. Int J Mol Sci. 2020 Jun 4;21(11):4026. | |||
